<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04287985</url>
  </required_header>
  <id_info>
    <org_study_id>VIS649-201</org_study_id>
    <secondary_id>2019-002531-29</secondary_id>
    <secondary_id>U1111-1263-1268</secondary_id>
    <nct_id>NCT04287985</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of VIS649 for IgA Nephropathy</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy and Safety of VIS649 in Participants With Immunoglobulin A (IgA) Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Visterra, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Visterra, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of VIS649 in participants&#xD;
      with immunoglobulin A (IgA) Nephropathy (IgAN)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, double-blind, randomized, placebo-controlled study in patients aged 18&#xD;
      years and above with biopsy confirmed diagnosis of IgAN. The study is designed to test the&#xD;
      safety and effectiveness of multiple doses of VIS649. The main objectives are to evaluate the&#xD;
      safety and tolerability of VIS649 and to evaluate the dose response of different doses of&#xD;
      VIS649 by measuring proteinuria.&#xD;
&#xD;
      The study is comprised of three main periods, Screening, Treatment (12 months) and Follow-Up&#xD;
      (4 months). Approximately 144 patients will be enrolled. The findings from this study will&#xD;
      form the basis for subsequent clinical development of VIS649.&#xD;
&#xD;
      VIS649 is a humanized immunoglobulin G (IgG2) monoclonal antibody that binds to and blocks&#xD;
      the biological actions of the cytokine A PRoliferation Inducing Ligand (APRIL), a key factor&#xD;
      in the production of aberrantly glycosylated IgA1 (a-g- IgA1), which is critical to the&#xD;
      pathogenesis of IgAN.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Patient, Investigator, Care Provider, Outcomes Assessor</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Assessment</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of adverse events graded by severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy Objective--effect on Proteinuria of repeated doses of VIS649 added to SOC (ACEI/ARB therapy) vs. SOC</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in uPCR (Urine protein/creatinine ratio) measured on natural log scale from 24-hour urine collection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of repeated doses of VIS649 added to SOC (ACEI/ARB therapy) vs. SOC plus placebo</measure>
    <time_frame>9 months</time_frame>
    <description>Change from baseline in uPCR (Urine protein/creatinine ratio)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of repeated doses of VIS649 added to SOC (ACEI/ARB therapy) vs. SOC plus placebo</measure>
    <time_frame>16 months</time_frame>
    <description>Change from baseline in uPCR (Urine protein/creatinine ratio)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of repeated doses of VIS649 added to SOC (ACEI/ARB therapy) vs. SOC on protein excretion</measure>
    <time_frame>9 months</time_frame>
    <description>Change from baseline in 24-hour urine protein excretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of repeated doses of VIS649 added to SOC (ACEI/ARB therapy) vs. SOC on protein excretion</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in 24-hour urine protein excretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of repeated doses of VIS649 added to SOC (ACEI/ARB therapy) vs. SOC on protein excretion</measure>
    <time_frame>16 months</time_frame>
    <description>Change from baseline in 24-hour urine protein excretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of repeated doses of VIS649 added to SOC (ACEI/ARB therapy) vs. SOC in achieving ≥ 30% decline from baseline in uPCR</measure>
    <time_frame>9 months</time_frame>
    <description>Number of patients with ≥ 30% decline from baseline in uPCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of repeated doses of VIS649 added to SOC (ACEI/ARB therapy) vs. SOC in achieving ≥ 30% decline from baseline in uPCR</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients with ≥ 30% decline from baseline in uPCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of repeated doses of VIS649 added to SOC (ACEI/ARB therapy) vs. SOC in achieving ≥ 30% decline from baseline in uPCR</measure>
    <time_frame>16 months</time_frame>
    <description>Number of patients with ≥ 30% decline from baseline in uPCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of repeated doses of VIS649 added to SOC (ACEI/ARB therapy) vs. SOC on proteinuria</measure>
    <time_frame>up to 16 months</time_frame>
    <description>Number of patients meeting protocol-defined criteria for remission in 24-hour urine protein excretion for protocol-specified period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of repeated doses of VIS649 added to SOC (ACEI/ARB therapy) vs. SOC on kidney function.</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in participant's eGFR (Estimated glomerular filtration rate).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of repeated doses of VIS649 added to SOC (ACEI/ARB therapy) vs. SOC on kidney function.</measure>
    <time_frame>16 months</time_frame>
    <description>Change from baseline in participant's eGFR (Estimated glomerular filtration rate).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of repeated doses of VIS649 added to SOC (ACEI/ARB therapy) vs. SOC in total serum IgA, IgG and IgM concentrations</measure>
    <time_frame>9 months</time_frame>
    <description>Change from baseline in participant's serum Ig concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of repeated doses of VIS649 added to SOC (ACEI/ARB therapy) vs. SOC in total serum IgA, IgG and IgM concentrations</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in participant's serum Ig concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of repeated doses of VIS649 added to SOC (ACEI/ARB therapy) vs. SOC in total serum IgA, IgG and IgM concentrations</measure>
    <time_frame>16 months</time_frame>
    <description>Change from baseline in participant's serum Ig concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum PK parameters</measure>
    <time_frame>up to month 16</time_frame>
    <description>Measurement of circulating VIS649 concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum anti-drug-antibody (ADA)</measure>
    <time_frame>up to 16 months</time_frame>
    <description>Measurement of circulating antibodies to VIS649</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Immunoglobulin A Nephropathy</condition>
  <condition>Glomerular Disease</condition>
  <condition>IgAN</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (0.9% NaCl) will be administered IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose - VIS649</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose of VIS649 administered IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium Dose - VIS649</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium dose of VIS649 administered IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose - VIS649</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose of VIS649 administered IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose-Placebo</intervention_name>
    <description>Unit Dose Strength - 0.9%.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose-VIS649</intervention_name>
    <description>Dose Level = Low</description>
    <arm_group_label>Low Dose - VIS649</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medium Dose-VIS649</intervention_name>
    <description>Dose Level = Medium</description>
    <arm_group_label>Medium Dose - VIS649</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Dose-VIS649</intervention_name>
    <description>Dose Level = High</description>
    <arm_group_label>High Dose - VIS649</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants are eligible to be included in the study only if all of the following criteria&#xD;
        apply:&#xD;
&#xD;
          1. Participant is a male or female ≥ 18 years of age at the time of signing the informed&#xD;
             consent.&#xD;
&#xD;
          2. Participant must have biopsy-confirmed IgAN.&#xD;
&#xD;
          3. Participant has medical records showing they have been on stable and maximally&#xD;
             tolerated doses of either ACEI or ARB, as per local SOC and applicable guidelines, for&#xD;
             at least 3 months preceding screening. Participants should optimally be on at least&#xD;
             50% of the maximum recommended dose of these agents; however, if a participant is on&#xD;
             their maximally tolerated dose (and this is &lt; 50% of the maximum recommended dose) and&#xD;
             has been on this dose for at least 3 months, they may be enrolled. Participants who&#xD;
             are unable to tolerate ACEI/ARB therapy may be eligible for participation in the study&#xD;
             if their overall management of IgAN, including BP control, is as per local SOC and&#xD;
             applicable guidelines.&#xD;
&#xD;
          4. Participants must have screening uPCR ≥ 0.75 g/g measured from a 24-hour urine or&#xD;
             24-hour urine protein ≥ 1.0 g/d, as measured from 24-hour urine collection. The&#xD;
             proteinuria should be assessed when the participant is considered to be in a steady&#xD;
             state with no recent heavy exercise, fever, or other potential issues that could&#xD;
             impact the result.&#xD;
&#xD;
          5. Participants must have eGFR ≥ 45 mL/min/1.73 m².&#xD;
&#xD;
          6. Participant's serum Ig values must meet specified criteria&#xD;
&#xD;
          7. Female participants of childbearing potential must have a negative serum pregnancy&#xD;
             test prior to the first dose.&#xD;
&#xD;
          8. Participant is willing to adhere to contraceptive requirements.&#xD;
&#xD;
          9. Participant or a legally authorized representative is able and is willing to give&#xD;
             voluntary written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants are excluded from the study if they meet any of the following criteria:&#xD;
&#xD;
          1. Participant has secondary forms of IgAN as defined by the treating physician.&#xD;
&#xD;
          2. Participant has co-existing CKD, other than IgAN.&#xD;
&#xD;
          3. Participant has evidence of additional pathological findings in the kidney biopsy (eg,&#xD;
             diabetic kidney disease, membranous nephropathy, or lupus nephritis). However,&#xD;
             hypertensive vascular changes are acceptable.&#xD;
&#xD;
          4. Participant has kidney biopsy MEST or MEST-C score as defined in the protocol.&#xD;
&#xD;
          5. Participant has nephrotic syndrome.&#xD;
&#xD;
          6. Participant has received a solid organ transplant, including kidney.&#xD;
&#xD;
          7. Participant has received bone marrow or hematologic stem cell transplantation.&#xD;
&#xD;
          8. Participant is currently receiving systemic immunosuppression (excluding topical,&#xD;
             ophthalmic, per rectum, or inhaled corticosteroids).&#xD;
&#xD;
          9. Participant has received treatment with systemic corticosteroid therapy within 16&#xD;
             weeks of initial screening.&#xD;
&#xD;
         10. Participant has received treatment with a systemic immunosuppressive agents within 16&#xD;
             weeks of initial screening.&#xD;
&#xD;
         11. Participant has any chronic infectious disease.&#xD;
&#xD;
         12. Participant has acute infectious disease at the time of screening.&#xD;
&#xD;
         13. Participant has Type 1 diabetes.&#xD;
&#xD;
         14. Participant has uncontrolled Type 2 diabetes, as evidenced by a screening hemoglobin&#xD;
             A1c value &gt; 8%.&#xD;
&#xD;
         15. Participant has uncontrolled BP (&gt; 140 mm Hg systolic or &gt; 90 mm Hg diastolic)&#xD;
&#xD;
         16. Participant has a history of chronic autoimmune neurodegenerative disorder such as&#xD;
             multiple sclerosis.&#xD;
&#xD;
         17. Participant has a known allergy or intolerance to any component of the study&#xD;
             intervention.&#xD;
&#xD;
         18. Participant is breastfeeding.&#xD;
&#xD;
         19. Participant has poorly compensated or controlled ischemic heart disease or&#xD;
             cardiomyopathy, as judged by the Investigator.&#xD;
&#xD;
         20. Participant has chronic obstructive pulmonary disease (COPD) or asthma that has&#xD;
             required systemic steroid therapy during the prior year.&#xD;
&#xD;
         21. Participant has known cirrhosis or liver dysfunction, defined as presence of&#xD;
             coagulopathy, platelet count &lt; 100,000/μL or alanine aminotransferase &gt; 3× upper limit&#xD;
             of normal.&#xD;
&#xD;
         22. Participant has active malignancy or is receiving chemotherapy for malignancy, except&#xD;
             for nonmelanoma skin cancers and cervical carcinoma in situ. Participants with prior&#xD;
             malignancy who have been documented to be cancer-free for ≥ 5 years may be enrolled.&#xD;
&#xD;
         23. Participant is planning or scheduled to undergo a tonsillectomy. Prior tonsillectomy&#xD;
             is acceptable (if greater than 6 months prior to screening).&#xD;
&#xD;
         24. Participant enrolled in another investigational drug or device study within 3 months&#xD;
             prior to initial screening.&#xD;
&#xD;
         25. Participant with a pre-existing illness other than those listed above that, in the&#xD;
             opinion of the Investigator, would place the participant at increased risk through&#xD;
             participation in this study.&#xD;
&#xD;
         26. Participant is unable to comply with study protocol procedures and/or study visit&#xD;
             schedules.&#xD;
&#xD;
         27. Participant with known or suspected alcohol or drug abuse that would compromise their&#xD;
             safety or study participation of the participant, in the opinion of the Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Oldach, M.D., FIDSA</last_name>
    <role>Study Director</role>
    <affiliation>Visterra, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Visterra Clinical Trial Information Line</last_name>
    <phone>617-498-1070</phone>
    <email>clinicaltrials@visterrainc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027-5969</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-2200</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121-2429</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201-1544</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054-2854</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>New Lambton Heights</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Saint Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Nambour</city>
        <state>Queensland</state>
        <zip>4560</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6R 3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <state>HK</state>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Kowloon</city>
        <zip>999077</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Tsuen Wan</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Chandigarh</city>
        <state>CH</state>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>New Delhi</city>
        <state>DL</state>
        <zip>110060</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <state>KA</state>
        <zip>560054</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Bengaluru</city>
        <state>KA</state>
        <zip>560034</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Manipala</city>
        <state>KA</state>
        <zip>576104</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Kozhikode</city>
        <state>KL</state>
        <zip>673008</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Thiruvananthapuram</city>
        <state>KL</state>
        <zip>695011</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <state>TG</state>
        <zip>500012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <state>TG</state>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Vellore</city>
        <state>TN</state>
        <zip>632004</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Raebareli</city>
        <state>UP</state>
        <zip>226014</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Toyoake-shi</city>
        <state>Aichi</state>
        <zip>470-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+1.617.498.1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Ashikaga</city>
        <state>Tochigi</state>
        <zip>326-0843</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+1.617.498.1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Ashikaga-Shi</city>
        <zip>326-0843</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Bunkyō-Ku</city>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Kashihara-shi</city>
        <zip>634-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Minato-Ku</city>
        <zip>470-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Nerima Ku</city>
        <zip>177-8521</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Niigata Shi</city>
        <zip>951-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Shinjuku-Ku</city>
        <zip>162-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Tsukuba Shi</city>
        <zip>305-876</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Urayasu-Shi</city>
        <zip>279-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Anyang</city>
        <state>Gyeonggi-do</state>
        <zip>14068</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+1.617.498.1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Anyang</city>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Dongdaemun-gu</city>
        <zip>130-872</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Gangdong</city>
        <zip>5355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Hwaseong-si</city>
        <zip>18450</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+1.617.498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>3080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>3722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Klang</city>
        <zip>41200</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>56000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Kuantan</city>
        <zip>25100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Seremban</city>
        <zip>70300</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Diliman</city>
        <zip>1101</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1102</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>L'Hospitalet De Llobregat</city>
        <state>B</state>
        <zip>8907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Santander</city>
        <state>CB</state>
        <zip>39010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Córdoba</city>
        <state>CO</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <state>SE</state>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>8025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+1.617.498.1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+1.617.498.1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Colombo</city>
        <zip>800</zip>
        <country>Sri Lanka</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Kandy</city>
        <zip>20000</zip>
        <country>Sri Lanka</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Nugegoda</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>82445</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Keelung</city>
        <zip>20104</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>New Taipei City</city>
        <zip>23142</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>New Taipei City</city>
        <zip>23561</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Xitun</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10310</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Ratchathewi</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Bradford</city>
        <zip>BD5 0NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>London</city>
        <zip>E11BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visterra Investigational Site</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-498-1070</phone>
      <email>clinicaltrials@visterrainc.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Hong Kong</country>
    <country>India</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Sri Lanka</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 10, 2020</study_first_submitted>
  <study_first_submitted_qc>February 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2020</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VIS649</keyword>
  <keyword>Kidney Diseases</keyword>
  <keyword>Glomerulonephritis, IGA</keyword>
  <keyword>Glomerulonephritis</keyword>
  <keyword>Nephritis</keyword>
  <keyword>Autoimmune Diseases</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Immunoglobulins</keyword>
  <keyword>Antibodies</keyword>
  <keyword>Immunoglobulin A</keyword>
  <keyword>Immunologic Factors</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Proteinuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

